Clinical Study Results Sanofi Pharma, including Sanofi Genzyme

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Etudes cliniques et résultats Sanofi pharma, incluant Sanofi Genzyme – Lettre F

GENERIC NAME	TRADE NAME	CONDITION	STUDY CODE	STUDY NAME	ACCESS TO STUDY / PROTOCOL	ACCESS TO RESULTS
FATTY ACID AMIDE HYDROLASE INHIBITOR	Not marketed	Cancer pain	ACT11705	NA	EudraCT: 2011-002557-56	Summary Results
FATTY ACID AMIDE HYDROLASE INHIBITOR	Not marketed	Major Depressive Disorder	DFI10560	FIDELIO	EudraCT: 2008-001718-26	Summary Results
FEDRATINIB	Not marketed	Myelofibrosis	ARD12888	NA	NCT01692366	Summary
FEDRATINIB	Not marketed	Myelofibrosis	ARD12888	NA	NCT01692366	Summary
FEDRATINIB	Not marketed	Hematopoietic Neoplasm	ARD12042	NA	NCT01420783	Summary
FEDRATINIB	Not marketed	Hematopoietic Neoplasm	ARD11936	NA	NCT01420770	Summary
FEDRATINIB	Not marketed	Neoplasm malignant	TES13519	NA	NCT01836705	Summary
FEDRATINIB	Not marketed	Hematopoietic Neoplasm	ARD12181	JAKARTA2	NCT01523171	Summary
FEDRATINIB	Not marketed	Myelofibrosis	EFC12153	JAKARTA	EudraCT: 2011-001897-25	Tabulated Results
FEDRATINIB	Not marketed	Solid Tumor	INT12497	NA	NCT01585623	Summary
FEDRATINIB	Not marketed	Renal Impairment	POP13449	NA	NCT01763190	Summary
FEDRATINIB	Not marketed	Hepatic Impairment	POP13450	NA	NCT01762462	Summary
FERROQUINE	Not marketed	Malaria	ACT10420	NA	NCT00563914	Publication reference
FERROQUINE	Not marketed	Malaria	ACT14655	NA	NCT03660839	Tabulated Results
FERROQUINE	Not marketed	Malaria	DRI10382	FARM	NCT00988507	Publication reference
FERROQUINE	Not marketed	Malaria	DRI12805	FALCI	NCT02497612	Tabulated Results
FEXOFENADINE HYDROCHLORIDE	Allegra	Urticaria	M016455_4001	NA	NA	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Urticaria	M016455A_4121	NA	NA	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Rhinitis, Seasonal	M016455_4124	NA	NCT00636870	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Cognition	M016455A_4139	NA	NCT00637455	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Urticaria	M016455A_4143	NA	NA	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Urticaria	M016455A_4144	NA	NCT00547768	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Seasonal allergy	M016455A_4145	NA	NCT00637585	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Seasonal allergy	M016455A_4146	NA	NCT00638118	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Cat allergy symptoms	M016455A_4148	NA	NCT00637884	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Seasonal Allergic Rhinitis	LPS15332	FEXPOLSAR	NCT03664882	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Seasonal Allergic Rhinitis	M016455A_4149	NA	NCT00637611	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Seasonal Allergic Rhinitis	M016455C_4001	NA	NCT00741897	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Rhinitis Perennial	SFY10717	NA	NCT01244217	Summary
FEXOFENADINE HYDROCHLORIDE	Allegra	Atopic Dermatitis	SFY10718	NA	NCT01244230	Summary
FEXOFENADINE HCL - PSEUDOEPHEDRINE HCL COMBINATION	Allegra-D	Rhinitis Perennial	EFC11243	NA	NCT01306721	Summary
FEXOFENADINE HCL - PSEUDOEPHEDRINE HCL COMBINATION	Allegra-D	Allergic Rhinitis	FEXHYL06934	NA	NCT02175485	Summary
FGFR NHIBITOR	Not marketed	Solid Tumors	PRN1371-001	NA	NCT02608125	Summary
FLUOROURACIL	Carac	Keratosis	DL6025-0201	NA	NCT00377273	Summary
FRESOLIMUMAB	Not Marketed	Glomerulosclerosis	GC1008FSGS03110	NA	EudraCT: 2012-002365-35	Tabulated Results
FUROSEMIDE	Lasix, Eutensin, Lasilix	Chronic Renal Failure	FUROSL06121	NA	NCT01724788	Summary
FITUSIRAN	Not marketed	Hemophilia A and B	EFC14768	ATLAS-INH	NCT03417102	Tabulated Results
FITUSIRAN	Not marketed	Hemophilia A and B	EFC14769	NA	NCT03417245	Tabulated Results
FITUSIRAN	Not marketed	Hemophilia	EFC15110	ATLAS-PPX	EudraCT: 2016-004087-19	Tabulated Results
FEXOFENADINE - PHENYLEPHRINE	Not Marketed	Allergic Rhinitis	FEXHYL07477	NA	NCT02401191	Summary
FRESOLIMUMAB	Not Marketed	Glomerulosclerosis	DRI12792	NA	EudraCT: 2012-002365-35	Tabulated Results

References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted